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Abstract
Purpose The study aims to evaluate a series of patients
with initial diagnosis of ocular histoplasmosis syndrome
(OHS) with progression and response to treatments consis-
tent with multifocal choroiditis (MFC).
Methods Retrospective review of nine patients referred for
management of recurrent OHS lesions. Serology panel was
conducted to rule out autoimmune and infectious causes.
Results Clinical examination revealed multiple small,
punched-out peripheral chorioretinal scars, and peripapil-
lary atrophy. Histoplasma antigen/antibody was negative in
all patients. Fluorescein angiography and optical coherence
tomography confirmed active inflammation in five patients.
Immunomodulatory therapy (IMT) was initiated to control
active inflammation. While on IMT, visual acuity stabilized
or improved in three patients with no recurrence of CNVor
lesion activities over the follow-up period.
Conclusions MFC may initially masquerade as OHS.
Clinical characteristics of recurrent MFC and absence of
histoplasma titer may lead to consideration of IMT and
other proper treatments for MFC.
Keywords Multifocal choroiditis . Ocular histoplasmosis
syndrome
Introduction
Differentiating between multifocal choroiditis (MFC) and
ocular histoplasmosis syndrome (OHS) may be challeng-
ing, especially if based solely on clinical examination. Both
may present with chorioretinal (CR) lesions and lack of
anterior chamber (AC)/vitreous inflammation [1]. Punched-
out chorioretinal scars, peripapillary scarring, and choroidal
neovascularization are present in both conditions [2].
However, as the management of OHS differs tremendously
from that of MFC, it is important to make proper diagnosis.
The index study evaluates a series of patients whose initial
diagnosis was OHS. Patients underwent extensive review of
systems, uveitis diagnostic survey, a comprehensive exam-
ination, and targeted evaluation. The subsequent progres-
sion and response to treatments in all patients were
consistent with MFC.
Materials and methods
Nine patients were referred from January 2008 to June
2010 to one of the authors (QDN) for management of OHS.
Patients were diagnosed and managed as subjects with OHS
E. Hatef : P. Turkcuoglu :M. Ibrahim :Y. Sepah :M. Shulman :
J. Heo : J. H. Lee :R. Channa :A. Khwaja : Z. Rentiya :
S. M. Shah :D. V. Do :Q. D. Nguyen (*)
Wilmer Eye Institute,
Johns Hopkins University School of Medicine,
600 North Wolfe Street–Maumenee 745,
Baltimore, MD 21287, USA
e-mail: qnguyen4@jhmi.edu
P. Turkcuoglu
Department of Ophthalmology,
Inonu University School of Medicine,
Malatya, Turkey
S. M. Shah
Flaum Eye Institute, University of Rochester School of Medicine,
Rochester,
New York, USA
J Ophthal Inflamm Infect (2011) 1:55–63
DOI 10.1007/s12348-010-0016-4
in their primary institutes; laser photocoagulation/vascular
endothelial growth factor (VEGF) antagonists for recurrent
choroidal neovascularization (CNV) and episodic predni-
sone for lesions causing visual disturbances were pre-
scribed. At the Wilmer Eye Institute, serology panel was
conducted to rule out autoimmune and infectious causes.
Fluorescein angiography (FA) and optical coherence to-
mography (OCT) were performed at initial and subsequent
visits.
The charts of eligible patients were reviewed to include
data regarding demographic features of each patient,
previous diagnosis of OHS and any concomitant diagnosis,
history of any relevant treatment to disease, and the length
of follow up. The results of comprehensive ocular exam-
ination, serologic workup for all possible inflammatory and
infectious conditions, as well as FA and OCT were
reviewed. Final diagnosis and treatment applied for each
patient was documented as well. Statistical summaries for
baseline characteristics were reported. The final diagnosis,
treatment regimen, and final outcomes for each patient were
presented.
Results
Eight women and one man with an age range of 26–
69 years (median: 38 years) were included in the study. Six
patients had a previous diagnosis of OHS, two had a likely
diagnosis of OHS or punctuate inner choroidopathy (PIC),
and one had a questionable diagnosis of uveitis and an
inflammatory/infectious process such as sarcoidosis or
OHS. Seven of the patients had a history of bevacizumab
injection to control CNV, one of whom also received laser
photocoagulation and photodynamic therapy; one had
photodynamic therapy as well as intraocular injection of
triamcinolone acetonide; the other one had photodynamic
therapy prior to bevacizumab injection. One patient had a
history of only laser photocoagulation to control CNV. The
patients were followed up at our institute for a period of
1.18–14.51 months (median; 3.16 months).
We carried out a comprehensive ocular examination as
well as serologic workup for all possible inflammatory and
infectious conditions based on the clinical findings.
Multiple small, punched-out peripheral CR scars and
peripapillary atrophy were noted in all patients. No
AC/vitreous inflammation was detected. None of them
had active CNV at the time of initial visit (Figs. 1 and 2).
Histoplasma antigen/antibody for all subjects was per-
formed in the same clinical laboratory through the Johns
Hopkins University and Hospitals, and both antigen and
antibody were negative in all patients.
Rheumatoid panel and serology for Herpes simplex as
well as Herpes zoster were also negative. FA and OCT
confirmed active inflammation (choroiditis without CNV)
in five patients. Table 1 shows the clinical and imaging
findings as well as serologic evaluation for each patient.
Based on the clinical examination and the result of
serologic evaluations that were nonrevealing for other
causes, a diagnosis of immune-mediated MFC was made
in seven patients. Patient 8 had a history of positive PPD
testing and ocular finding which might be consistent with
tuberculous choroiditis. We recommended the patient to be
evaluated for tuberculosis infection as well. For patient 9,
based on the clinical findings and negative serology for
histoplasmosis, it was most likely that he had CNV, which
is idiopathic in nature. There did not seem to be any active
CNV at the time of examination. Therefore, the patient was
advised to monitor his vision closely and be re-examined
regularly to look for any signs of CNV activity.
Immunomodulatory therapy (IMT) was initiated to
control the inflammation in five of the eight patients
(patients 1, 2, 5, 6, and 7). They received treatment from
1.84 to 6.22 months. Patient 3 had a complicated medical
history of scleroderma, graft-versus-host disease after an
allogenic bone marrow transplant for leukemia, history of
cytomegalovirus encephalopathy, and shingles. She was on
mycophenolate mofetil for scleroderma and graft-versus-
host disease at the time of initial visit. Considering the
underlying hematologic disease, we recommended a con-
sultation with her hematologist/oncologist prior to starting
treatment for MFC. For patient 4, based on examination
and ancillary testing, it was most likely that she had
primary MFC rather than OHS or toxoplasmosis. We
decided to monitor the patient and would begin IMT
treatment to decrease the risk of recurrent inflammation if
active choroiditis or recurrent CNV reappeared. In addition,
VEGF antagonist would be employed as needed to provide
rapid control of any recurrent CNV.
While on IMT, visual acuity stabilized or improved in
patients 2, 5, and 6 with no recurrence of CNV or lesion
activities over the follow-up period. These three patients
were followed up for a period of 3.16, 1.84, and
5.69 months, respectively. Patient 1 had an episode of
visual disturbance in the right eye which was accompanied
with an enlargement of two previously detected lesions on
OCT. The disease activation was not controlled by increase
in the dose of IMT; therefore, the patient was enrolled in a
clinical trial of local treatment of another IMT. Patient 7
had a worsening of visual acuity in the right eye from 20/
200 to 20/320 after initiation of IMT (mycophenolate
mofetil). Considering the short period of IMT treatment
and slow treatment response in the case of IMT, we decided
to continue our recommended treatment and follow up the
patient every 4 weeks. The visual acuity improved to
20/200, 3 months after initiation of IMT and the dosage was
increased to 1.5 g twice a day at the last visit. Patient 4 and
56 J Ophthal Inflamm Infect (2011) 1:55–63
9 had stable disease at the most recent visits and were thus
being observed on no IMT. As mentioned, patient 8 was
being evaluated by the Infectious Diseases Service for
possible tuberculosis infection. Since she did not have any
active lesion, we decided to observe her until a definitive
diagnosis was identified.
At the last visit, the visual acuity among all patients
has changed from 20/20–20/250 (median; 20/80) to
20/16–20/200 (median; 20/125) in the right eye and from
20/20–20/400 (median; 20/63) to 20/16–8/320 (median;
20/32) in the left eye.
Additional details on IMT and treatment response for
each patient are presented in Table 1. In addition, imaging
studies of patients with diagnosis of MFC showed decrease
in the amount of fluorescence of the lesions on autofluor-
escence among those being treated with IMT.
Discussion
Patients with MFC may masquerade as OHS. The index
study suggests that the diagnosis of OHS should not be
considered exclusively unless accompanied by positive
serology, absence of inflammation, and appropriate clinical
course for OHS. Even then, the patients should be followed
closely for progression of the lesions as the disease may be
of different entities. Our patients had many features that
resembled OHS. Peripheral and posterior pole scars like
Fig. 2 a Fundus image of the right eye of patient 5 illustrates multiple
chorioretinal lesions, which concentrates within the macula. There is a
deep chorioretinal scar on the temporal aspect of foveal center with no
subretinal fluid. b, c Fluorescein angiography of right eye demon-
strates classical choroidal neovascularization (CNV) filling pattern
with chorioretinal anastomosis in the center without prominent
leakage in early b and mid c phases. d, e Optical Coherence
Tomography of right eye shows hyperreflective substance within the
retinal pigment epithelium (RPE)/choroid complex, with no intra-
retinal edema
Fig. 1 The Optos™ P-200°
digital fundus image of patient 6
illustrates chorioretinal lesions
inferiorly in both eyes. Lesions
in the left eye are more
prominent than those in the
right eye. There is a yellowish
lesion just inferonasal to foveal
center of the left eye
J Ophthal Inflamm Infect (2011) 1:55–63 57
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those seen in OHS were present in our patients. However,
the chorioretinal lesions resulted from inflammatory pro-
cesses may be similar to those in OHS, with pigmented
borders and centers.
An enlarged blind spot at the time of presentation with
acute lesions or thereafter when the lesions are inactive has
been reported in patients with MFC [3]. For patient 5, the
Amsler visual testing revealed the presence of an old
scotoma in the nasal aspect of the field as well as a newer
small scotoma in the temporal aspect of the right visual
field. Multifocal chorioretinal lesions were seen in every
patient. The lesions were generally smaller and more
numerous than the typical histoplasma spots in OHS [4,
5]. There was a predominance of women similar to other
reports on MFC [1, 2]. The histoplasma antigen/antibody,
performed in the same laboratory was negative in all our
patients. Previously, serologic testing for Histoplasma
capsulatum used to have relatively low sensitivity with
positive result in 15% of the patients [2]. The recently
available serologic testing for H. capsulatum antigen is
highly sensitive. If it is disseminated histoplasmosis in an
immunocompetent patient, the sensitivities in serum and
urine samples are 82% and 92%, respectively; specificity is
98% and its reproducibility is excellent [6]. In those with
limited pulmonary disease, the sensitivities in serum and urine
samples are 68.6% and 64.6%, respectively [7]. In antibody
test against H. capsulatum, the positive immunodiffusion
reactions involve one or more specific precipitin bands. Of
these bands, the first to appear in active histoplasmosis is the
″M″ band, which is seen in approximately 70% of proven
cases. The M band is also seen in a number of patients with
past infections and in 20% of those with recent Histoplasma
skin testing. The ″H″ band is usually seen in active and
progressive histoplasmosis and almost always exists in the
presence of the ″M″ band, although it is found less often in
approximately 10% of proven cases (Quest Diagnostics
Nichols Institute, 14225 Newbrook Drive, Chantilly, VA
20153, and Immuno Mycologics, Inc (Immy) [8]).
Evidence of Epstein–Barr virus (EBV) infection was
detected in one of our patients, which is consistent with
Tiedeman’s report [9] about the possible relationship
between MFC and recent EBV infection.
The lesions observed in patients in the index study were
also different from those in PIC, which typically do not
have inflammatory signs, cells, or vitreous inflammation,
and often constitute a cluster of macular lesions [1]. PIC
patients have chorioretinal scars mostly in the posterior pole
and the clinical course is less likely complicated by
recurrent inflammation. The visual prognosis is usually
stable unless CNV develops. Unlike PIC, patients with
MFC have chorioretinal scars mostly in the mid-peripheral
retina and a course characterized by waxing and waning
inflammation that results in poor visual prognosis [10].
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The imaging findings in the index study supported the
MFC lesions and were consistent with the lesions described
as MFC in other studies [11, 12]. Retinal pigment epithelium
(RPE) was altered on OCT images. The hyper-fluorescent
leakage on FA images as well as hypo-fluorescence on
autofluorescene was consistent with previous descriptions of
MFC. These spots were associated with chorioretinal scars
and atrophy or absence of RPE cells detected in the posterior
pole of affected eyes [11, 12].
Once the patients were thought to have MFC with
recurrent diseases, corticosteroids and IMT were initiated,
which led to full control (no recurrences) of inflammation
and preservation of vision secondary to absence of active
inflammation [13]. IMT also allowed tapering of dosages of
corticosteroids to avoid long-term complications.
The current study emphasizes the importance of consid-
ering the possibility of other diagnoses when the disease
has atypical characteristics and behavior. Based on our
experience, when the actual chorioretinal lesions are
inflamed in the presence of an inactive CNV, the diagnosis
of OHS might be in doubt and should be reconsidered, and
different treatment approach might be required.
However, we also recognize the many limitations of our
study. The index study is a retrospective review of a small
number of patients. Many of the patients were followed for
only a short period of time. Longer follow-up time in a large
group of patients will provide more information regarding the
challenges in the diagnosis and management of MFC
masquerading as other conditions such as OHS and will also
help to confirm that treatment with IMT decreases recurrences
of diseases, as expected in MFC, and not in OHS. We also
recognize that many patients might not have presented with
appropriate information and history to aid the referring
physicians to consider MFC as possible etiologies.
Differentiation between MFC and OHS can be quite
challenging, especially when both conditions are quiescent
and there has been no previous examination or documentation
of the appearance of the fundus [1]. Serologic testing for H.
capsulatum, which is recently available with high sensitivity,
should be employed to aid in the management of such
patients, as absence of histoplasma titer and clinical character-
istics of recurrent MFC may be more supportive for a
diagnosis of (inflammatory) MFC and may lead to consider-
ation of IMT and other appropriate treatments for MFC.
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